A current examine revealed in JAMA has raised considerations concerning the potential dangers related to widespread weight reduction and diabetes medication like Novo Nordisk A/S’s NVO, Wegovy (semaglutide), Ozempic (semaglutide), and Saxenda (liraglutide).
The examine means that these medication, generally known as GLP-1s, could also be linked to 3 uncommon however extreme abdomen circumstances in non-diabetic sufferers.
Additionally Learn: Novo Nordisk’s Wegovy Success Uplifts Denmark’s Financial system And Fame, However With Warning.
Researchers discovered that the circumstances recognized within the examine embody abdomen paralysis, bowel obstruction, and pancreatitis. Notably, abdomen paralysis, which might result in signs like persistent vomiting, will not be presently listed as a warning on the drug labels.
The examine targeted on semaglutide, the lively ingredient in Wegovy and Ozempic, and in contrast it to a different weight reduction remedy known as bupropion-naltrexone.
Primarily based on medical insurance declare information for round 16 million U.S. sufferers, the examine findings revealed that GLP-1s had been related to a considerably increased threat of pancreatitis, bowel obstruction, and abdomen paralysis than bupropion-naltrexone.
The researchers particularly examined people with a current historical past of weight problems who had been prescribed semaglutide or liraglutide between 2006 and 2020. They intentionally excluded people with diabetes or these prescribed every other diabetes medicine.
The FDA has up to date the labeling for Novo Nordisk’s Ozempic to incorporate warnings about reported blocked intestines following its use.
Value Motion: NVO shares are up 0.38% at $90.32 in the course of the premarket session on the final verify Friday.
Supply Hyperlink : white119.com